Summary
This article reviews the clinical features and emphasises the treatment of polymyositis and dermatomyositis. Pharmacological intervention with corticosteroids and immunosuppressive agents is discussed. In addition, strategies regarding the initiation and subsequent tapering of these drugs are provided, and an algorithmic approach to the management of myositis is provided. Therapeutic modalities for patients with refractory disease are considered, and the potential adverse effects of such treatment are discussed. Since patients with myositis often have disease-related complaints other than muscle weakness, a practical treatment approach for these problems is also outlined.
Similar content being viewed by others
References
Berger RG, Hadler NM. Treatment of Calcinosis universalis secondary to dermatomyositis or scleroderma with low-dose warfarin. Abstract. Arthritis and Rheumatism 26 (Suppl.): S11, 1983
Bohan A, et al. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56: 255–286, 1977
Bohan A, Peter JB. Polymyositis and dermatomyositis. New England Journal of Medicine 292: 344–347, 403–407, 1975
Bradley WG. Inflammatory disease of muscle. In Kelly et al. (Eds) Textbook of rheumatology, 2nd ed., pp. 1225–1245, WB Saunders Company, Philadelphia, 1985
Bunch TW, et al. Azathioprine with prednisolone for polymyositis. Annals of Internal Medicine 92: 365–369, 1980
Bunch TW. Prednisone and azathioprine for polymyositis. Arthritis and Rheumatism 24(1): 45–48, 1981
Callen JP. Dermatomyositis. Disease-a-Month 33(5): 239–305, 1987
Cronin ME, et al. Intravenous cyclophosphamide in idiopathic inflammatory myopathy. Abstract. Arthritis and Rheumatism 31 (Suppl.): S122, 1988
Dau PC. Plasmapheresis in idiopathic inflammatory myopathy: Experience with 35 patients. Archives of Neurology 38: 544–552, 1981
Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. American Journal of Medicine 80: 329–332, 1986
Jones DW, et al. Cyclosporine treatment for intractable polymyositis (letter). Arthritis and Rheumatism 30(8): 959–960, 1987
Kagen LJ, Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis and Rheumatism 30(2): 213–217, 1987
Laxer RM, et al. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis and Rheumatism 30(3): 328–334, 1987
Lemmer JP, et al. Clinical characteristics and course in patients with high titer anti-RNP antibodies. Journal of Rheumatology 9: 536–542, 1982
Maddison PJ, et al. Pattern of clinical disease associated with antibodies to nuclear ribonucleoprotein. Journal of Rheumatology 5: 407–411, 1978
Medsger Jr TA, et al. The epidemiology of polymyositis. American Journal of Medicine 48: 715–723, 1970
Metzger AL, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Annals of Internal Medicine 81: 182–189, 1974
Mitchell MS, et al. Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Annals of Internal Medicine 70: 535–546, 1969
Morgan SH, et al. Total body irradiation and the course of polymyositis. Arthritis and Rheumatism 28(7): 831–835, 1985
Oddis CV, Medsger Jr TA. Relationship between serum CPK level and corticosteroid therapy in polymyositis-dermatomyositis. Journal of Rheumatology 15: 807–811, 1988
Pearson CM. Polymyositis and dermatomyositis. In Hollander et al. (Eds) Arthritis and allied conditions, 8th ed., p. 940, Lea and Febiger, Philadelphia, 1972
Roifman CM, et al. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. Journal of the American Medical Association 258(4): 513–515, 1987
Silverman G, et al. Anti-Jo-1 antibody, arthritis and interstitial lung disease in black patients with polymyositis. Arthritis and Rheumatism (abstract) 30 (Suppl.): S39, 1987
Sokoloff MC, et al. Treatment of corticosteroid-resistant polymyositis with methotrexate. Lancet 1: 14–16, 1971
Tiliakos NA. Low-dose cytotoxic combination treatment in intractable dermatopolymyositis. Arthritis and Rheumatism (abstract) 30 (Suppl.): S14, 1987
Treadwell EL, et al. Clinical relevance of PM-1 antibody and physiochemical characterization of PM-1 antigen. Journal of Rheumatology 11: 658–662, 1984
Wallace DJ. Combination immunosuppressive treatment of steroid resistant dermatomyositis/polymyositis. Arthritis and Rheumatism 28(5): 590–592, 1985
Woo TY, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. Journal of the American Academy of Dermatology 10: 592–600, 1984
Yoshida S, et al. The precipitating antibody to an acidic nuclear protein antigen, Jo-1, in connective tissue disease. Arthritis and Rheumatism 26: 604–661, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oddis, C.V., Medsger, T.A. Current Management of Polymyositis and Dermatomyositis. Drugs 37, 382–390 (1989). https://doi.org/10.2165/00003495-198937030-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198937030-00007